Welcome to our dedicated page for Kura Oncology news (Ticker: KURA), a resource for investors and traders seeking the latest updates and insights on Kura Oncology stock.
Kura Oncology, Inc. (Nasdaq: KURA) is a biopharmaceutical company focused on precision medicines for cancer, and its news flow reflects the evolution of this strategy. Company announcements highlight progress with KOMZIFTI (ziftomenib), an oral menin inhibitor approved in the United States for adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible NPM1 mutation who have no satisfactory alternative treatment options.
News items for KURA commonly cover regulatory milestones, clinical data and commercial updates. Recent releases describe full FDA approval of KOMZIFTI, its addition to the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology as a Category 2A recommended option for relapsed or refractory NPM1-mutated AML, and the start of U.S. commercial sales. Kura also reports on its collaboration with Kyowa Kirin, including milestone payments tied to clinical and commercial events.
Investors following KURA news can expect detailed coverage of clinical trial readouts from programs such as KOMET-001, KOMET-007 and KOMET-017, which evaluate ziftomenib across newly diagnosed and relapsed or refractory AML, often in combination with regimens like cytarabine/daunorubicin and venetoclax/azacitidine. Additional news addresses the company’s farnesyl transferase inhibitor programs, darlifarnib and tipifarnib, and their activity in solid tumors.
Kura’s press releases also include corporate updates such as financial results, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and participation in scientific and investor conferences. For readers tracking KURA, this news page offers a centralized view of key developments in its precision oncology pipeline, regulatory interactions, collaborations and commercialization activities.
Kura Oncology (Nasdaq: KURA) announced that on October 1, 2025 its Compensation Committee granted inducement awards under the 2023 Inducement Option Plan to seven new employees.
The awards consist of 122,250 nonstatutory stock options with an exercise price of $9.20 per share (closing price on October 1, 2025). Options vest over four years: 25% at the one-year anniversary and the remainder monthly over 36 months, subject to continued service, and are governed by the plan and option agreements.
Kura Oncology (NASDAQ:KURA) and Kyowa Kirin (TSE:4151) have initiated patient dosing in a new cohort of the KOMET-007 clinical trial, evaluating the combination of ziftomenib with cytarabine, daunorubicin, and quizartinib in newly diagnosed acute myeloid leukemia (AML) patients.
The trial targets patients with FLT3/NPM1 co-mutations, which affect approximately 30% of newly diagnosed adult AML patients and up to 50% of adult patients with NPM1-mutated AML. Ziftomenib, which has received FDA Breakthrough Therapy Designation for treating adult patients with relapsed/refractory NPM1-mutated AML, will be evaluated for safety, tolerability, and activity in combination with intensive chemotherapy and quizartinib.
Kura Oncology (NASDAQ:KURA) and Kyowa Kirin (TSE:4151) have announced the dosing of the first patient in their pivotal Phase 3 KOMET-017 trial for ziftomenib, an investigational menin inhibitor for frontline Acute Myeloid Leukemia (AML) treatment.
The trial consists of two independent global studies evaluating ziftomenib in combination with both intensive and non-intensive regimens for patients with newly diagnosed NPM1-mutated or KMT2A-rearranged AML. The intensive chemotherapy trial will assess MRD negative CR and EFS as dual-primary endpoints, while the non-intensive trial will evaluate CR and overall survival. The studies are designed to support potential U.S. accelerated and full approval.
The trial will enroll patients across 200 sites worldwide and targets nearly half of newly diagnosed AML patients. This program is notable as the only menin inhibitor actively pursuing registrational trials across both intensive and non-intensive chemotherapy settings.
Kura Oncology (NASDAQ:KURA) and Kyowa Kirin announced the publication of pivotal KOMET-001 trial results for ziftomenib in the Journal of Clinical Oncology. The trial, evaluating this oral menin inhibitor in relapsed/refractory NPM1-mutated AML patients, met its primary endpoint with a CR/CRh rate of 22%, significantly exceeding the 12% historical standard.
Key findings include a 33% overall response rate, median overall survival of 6.6 months, and 61% MRD-negative rate among CR/CRh responders. The drug showed consistent efficacy across subgroups and demonstrated a favorable safety profile. The FDA has set a PDUFA date of November 30, 2025 for priority review.
[ "Met primary endpoint with CR/CRh rate of 22%, significantly higher than 12% historical standard", "61% of CR/CRh responders achieved MRD-negative status", "Favorable safety profile with low discontinuation rate (3%)", "Consistent efficacy across patient subgroups regardless of prior treatments", "FDA granted Priority Review with PDUFA date set for November 30, 2025" ]Kura Oncology (NASDAQ:KURA), a clinical-stage biopharmaceutical company focused on precision medicines for cancer treatment, has announced its upcoming participation in the UBS Virtual Oncology Day. The management presentation is scheduled for October 1, 2025, at 2:30 p.m. ET.
Investors can access the live audio webcast through the Investors section of Kura's website, with a replay available after the event.
Kura Oncology (NASDAQ:KURA) hosted an analyst/investor event showcasing preclinical data for its farnesyl transferase inhibitor (FTI) program, specifically highlighting KO-2806 (darlifarnib). The data demonstrates the potential of FTIs to overcome drug resistance when combined with PI3Kα inhibitors, KRAS inhibitors, and antiangiogenic tyrosine kinase inhibitors (TKIs) across multiple tumor types.
The company's next-generation FTI, KO-2806, shows superior potency and enhanced properties compared to first-generation candidates. Preclinical studies revealed that FTIs effectively suppress mTOR signaling and demonstrate the potential to impact over 200,000 incident patients annually in the U.S. across various cancers including renal cell carcinoma, neuroendocrine tumors, NSCLC, colorectal cancer, and breast cancer.
Preliminary clinical data for KO-2806 will be presented at the ESMO Congress 2025 in October, with three scheduled presentations.
Kura Oncology (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on precision cancer medicines, has announced inducement grants to seven new employees. The Compensation Committee approved nonstatutory stock options to purchase 82,950 shares of common stock under the company's 2023 Inducement Option Plan.
The stock options have an exercise price of $7.95 per share, matching the closing price on September 2, 2025. The options will vest over four years, with 25% vesting after one year and the remainder vesting monthly over the following 36 months, contingent on continued employment.
Kura Oncology (Nasdaq: KURA) has announced two upcoming virtual investor and analyst events focused on their farnesyl transferase inhibitor (FTI) program. The first event on September 16, 2025, will showcase preclinical data on combining FTI agents with targeted therapies including TKIs, RAS inhibitors, and PI3K alpha inhibitors.
The second event on October 18, 2025, will present clinical data from the ESMO Congress 2025, featuring the first clinical data from KO-2806, Kura's next-generation FTI. The company will present three posters at ESMO, including preliminary results from the FIT-001 phase 1 trial combining KO-2806 with cabozantinib in renal cell carcinoma, KO-2806 monotherapy data in advanced solid tumors, and Phase 1 results from the KURRENT-HN study.
Kura Oncology (NASDAQ:KURA), a clinical-stage biopharmaceutical company focused on precision medicines for cancer treatment, has announced its participation in three major investor conferences in September 2025.
The company will present at the Cantor Global Health Conference on September 4 at 8:35 a.m. ET, the H.C. Wainwright Global Investment Conference on September 8 at 1:00 p.m. ET, and the Morgan Stanley Global Healthcare Conference on September 10 at 1:50 p.m. ET. Live webcasts will be available on Kura's website with archived replays accessible after the events.
Kura Oncology (NASDAQ: KURA) reported Q2 2025 financial results and significant progress in its oncology pipeline. The FDA granted Priority Review for ziftomenib in relapsed/refractory NPM1-mutant AML with a PDUFA date of November 30, 2025. The company reported $15.3 million in collaboration revenue and ended Q2 with $630.7 million in cash.
Key clinical achievements include positive results from the KOMET-001 pivotal trial showing a 23% complete remission rate and promising data from KOMET-007 Phase 1b expansion cohort. The company plans to initiate two Phase 3 trials in frontline AML settings in 2H 2025 and will present three clinical abstracts from its FTI program at the 2025 ESMO Congress.
Q2 2025 resulted in a net loss of $66.1 million, with R&D expenses of $62.8 million and G&A expenses of $25.2 million. Current cash runway extends into 2027.